Long-term outcomes of mesohepatectomy for centrally located liver tumors

• Verfasst von: Mehrabi, Arianeb [VerfasserIn]
• Verfasst von: Ramouz, Ali [VerfasserIn]
• Verfasst von: Golriz, Mohammad [VerfasserIn]
• Verfasst von: Khajeh, Elias [VerfasserIn]
• Verfasst von: Hackert, Thilo [VerfasserIn]
• Verfasst von: Müller, Beat P. [VerfasserIn]
• Verfasst von: Strobel, Oliver [VerfasserIn]
• Verfasst von: Hoffmann, Katrin [VerfasserIn]
• Verfasst von: Büchler, Markus W. [VerfasserIn]
• Verfasst von: Ünal, Umut Kaan [VerfasserIn]
• Verfasst von: Ghamarnejad, Omid [VerfasserIn]
• Verfasst von: Mieth, Markus [VerfasserIn]
• Verfasst von: Abbasi Dezfouli, Sepehr [VerfasserIn]
• Verfasst von: Weiss, Karl Heinz [VerfasserIn]
• Verfasst von: Chang, De-Hua [VerfasserIn]
• Verfasst von: Springfeld, Christoph [VerfasserIn]
• Verfasst von: Goeppert, Benjamin [VerfasserIn]
• Verfasst von: Longerich, Thomas [VerfasserIn]
• Titel: Long-term outcomes of mesohepatectomy for centrally located liver tumors
• Titelzusatz: two-decade single-center experience
• Verf.angabe: Arianeb Mehrabi, MD, FACS, Ali Ramouz, MD, Mohammad Golriz, MD, MD, Elias Khajeh, MD,Thilo Hackert, MD, Beat Müller-Stich, MD, Oliver Strobel, MD, Katrin Hoffmann, MD, Markus W Büchler, MD, FACS, Liver Cancer Center Heidelberg (LCCH)
• Jahr: 2022
• Umfang: 10 S.
• Fussnoten: Members of the Liver Cancer Center Heidelberg (LCCH): Umut Kaan Ünal, Omid Ghamarnejad, Markus Mieth, Sepehr Abbasi Dezfouli, Department of General, Visceral, and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany; Karl Heinz Weiss, Liver Cancer Center Heidelberg and Department of Internal Medicine, Heidelberg University Hospital, Heidelberg, Germany; De-Hua Chang, Liver Cancer Center Heidelberg and Department of Interventional Radiology, Heidelberg University Hospital, Heidelberg, Germany; Christoph Springfield, MD, Liver Cancer Center Heidelberg and National Center for Tumor Diseases, Department of Oncology, Heidelberg University Hospital, Heidelberg, Germany; Benjamin Goeppert, MD, Thomas Longerich, MD, Liver Cancer Center Heidelberg and Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany ; Christoph Springfeld ist in der Vorlage fälschlich als Christoph Springfield angegeben ; Gesehen am 30.08.2022
• Titel Quelle: Enthalten in: American College of SurgeonsJournal of the American College of Surgeons
• Ort Quelle: [Philadelphia, Pa.] : Wolters Kluwer Health, 1997
• Jahr Quelle: 2022
• Band/Heft Quelle: 235(2022), 2, Seite 257-266
• ISSN Quelle: 1879-1190
• DOI: doi:10.1097/XCS.0000000000000209
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 181536419X

Abstract

Export - BACKGROUND: Mesohepatectomy is a viable treatment option for patients diagnosed with centrally located liver tumors (CLLTs). There are several reports from Eastern centers, but few data are available on this topic from Western centers. - STUDY DESIGN: - Data of 128 consecutive patients who underwent mesohepatectomy between September 2000 and September 2020 in our center were analyzed from a prospectively collected database. Patient demographic data, liver tumor characteristics, and intraoperative data were collected. In addition, posthepatectomy bile leakage (PHBL), posthepatectomy hemorrhage (PHH), posthepatectomy liver failure (PHLF), and 90-day mortality after mesohepatectomy were assessed. Long-term outcomes were also reported, and factors that may influence disease-free survival were evaluated. - RESULTS: - Of 128 patients, 113 patients (88.3%) had malignant hepatic tumors (primary and metastatic tumors in 41 [32%] and 72 [56.3%] patients, respectively), and 15 patients suffered from benign lesions (11.7%). Among the relevant surgical complications (grade B or C), PHBL was the most common complication after mesohepatectomy and occurred in 11.7% of patients, followed by PHLF in 3.1% of patients and PHH in 2.3% of patients. Only four patients (3.1%) died within 90 days after mesohepatectomy. The 5-year overall survival and overall recurrence (for malignant lesion) rates were 76.5% and 45.1%, respectively. - CONCLUSION: - Mesohepatectomy is a safe and feasible surgical treatment with low morbidity and mortality for patients with CLLT. Long-term outcomes can be improved by increased surgical expertise.